Immune Pharmaceuticals (IMNP) Receiving Somewhat Favorable Media Coverage, Report Finds
News headlines about Immune Pharmaceuticals (NASDAQ:IMNP) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.4632654318901 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- IMMUNE PHARMACEUTICALS : Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits (form 8-K/A) (4-traders.com)
- Is Immune Pharmaceuticals Inc’s (NASDAQ:IMNP) CEO Salary Justified? (finance.yahoo.com)
- Immune Pharmaceuticals Announces Change in Certifying Accountant (di.se)
- May This Data Fuel Up Investor’s Confidence – Immune Pharmaceuticals Inc., (NASDAQ: IMNP) – Stock Watch (stocksnewstimes.com)
- Immune Pharmaceuticals Announces 2017 Annual Shareholder Meeting (di.se)
Shares of Immune Pharmaceuticals (NASDAQ IMNP) opened at $0.71 on Friday. Immune Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $5.02. The company has a debt-to-equity ratio of 3.04, a current ratio of 0.03 and a quick ratio of 0.03.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.